NYSE:ABBVBiotechs
How Investors May Respond To AbbVie (ABBV) Leaning On Hematology And Migraine Portfolios Beyond Legacy Blockbusters
In recent days, AbbVie has reported new hematology data at the EHA 2026 Congress, advanced its CLL and migraine portfolios in Europe, and managed smaller regulatory items such as an ophthalmic recall and FDA withdrawal of certain no-longer-marketed generics.
Together, these updates highlight how AbbVie is leaning on hematology and neuroscience assets, including venetoclax combinations and AQUIPTA, to broaden revenue sources beyond its legacy blockbusters.
Next, we will examine how AbbVie’s...